Urology
 |
|
28 november 2019 22:00:23 |
| Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors (European Urology Oncology) |
|
Tweet Targeted therapy has clinical activity following immuno-oncology (IO) treatment. Patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors versus mammalian target of rapamycin inhibitors following IO therapy had improved clinical outcomes. |
| 301 viewsCategory: Oncology, Urology |
 The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy (European Urology Oncology)Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy (European Urology Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page